SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.

IF 1.3 4区医学 Q4 INFECTIOUS DISEASES

Antiviral Therapy Pub Date : 2020-01-01 DOI:10.3851/IMP3365

Elise J Smolders, Lindsey Hm Te Brake, David M Burger

引用次数: 5

Abstract

Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2, lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al. in the New England Journal of Medicine showed that lopinavir/ritonavir treatment did not accelerate clinical improvement compared with standard of care. This raised the question of whether in retrospect we could have known this. The aim of this paper is to gather all the available evidence and to comprehensively discuss this issue.

查看原文本刊更多论文

SARS-CoV-2和HIV蛋白酶抑制剂:洛匹那韦/利托那韦对COVID-19感染无效的原因

自严重急性呼吸综合征(SARS)冠状病毒(CoV) 2暴发开始以来，选择洛匹那韦/利托那韦进行治疗。Cao等人最近在《新英格兰医学杂志》上发表的文章显示，与标准治疗相比，洛匹那韦/利托那韦治疗并没有加速临床改善。这就提出了一个问题:回想起来，我们是否知道这一点。本文的目的是收集所有可用的证据，并全面讨论这一问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antiviral Therapy 医学-病毒学

CiteScore

2.60

自引率

8.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Antiviral Therapy (an official publication of the International Society of Antiviral Research) is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases. Antiviral Therapy is one of the leading journals in virology and infectious diseases. The journal is comprehensive, and publishes articles concerning all clinical aspects of antiviral therapy. It features editorials, original research papers, specially commissioned review articles, letters and book reviews. The journal is aimed at physicians and specialists interested in clinical and basic research.